Bevacizumab on the PBS.
Kingston
David
D
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001315:Australia; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D017277:Drug Approval; D006297:Health Services Accessibility; D006801:Humans
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab